Ramucirumab plus FOLFIRI as second-line treatment for patients with RAS wild-type metastatic colorectal cancer previously treated with anti-EGFR antibody: JACCRO CC-16-Reference-Cited by-同舟云学术

Ramucirumab plus FOLFIRI as second-line treatment for patients with RAS wild-type metastatic colorectal cancer previously treated with anti-EGFR antibody: JACCRO CC-16

Published:2023-10 Issue:5 Volume:8 Page:101636
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Yasui H.,Okita Y.,Nakamura M.,Sagawa T.,Watanabe T.,Kataoka K.,Manaka D.,Shiraishi K.,Akazawa N.,Okuno T.,Shimura T.,Shiozawa M.,Sunakawa Y.,Ota H.,Kotaka M.,Okuyama H.,Takeuchi M.,Ichikawa W.,Fujii M.,Tsuji A.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference25 articles.

1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021

2. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study

3. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen;Van Cutsem;J Clin Oncol,2012

4. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial;Bennouna;Lancet Oncol,2013

5. Treatment of patients with late-stage colorectal cancer: ASCO resource-stratified guideline;Chiorean;JCO Glob Oncol,2020

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A multicenter, prospective, phase II trial of second‐line aflibercept plus FOLFIRI in patients with metastatic colorectal cancer refractory to an anti‐EGFR antibody: HGCSG1801;International Journal of Cancer;2024-08-14

2. Evaluation of the efficacy and safety of ramucirumab combined with nab-paclitaxel, lobaplatin, and S-1 in neoadjuvant and conversion therapy for advanced gastric cancer: A study protocol of prospective single-center, randomized controlled and open label clinical trial (RNPLS-01);Heliyon;2024-04